APO-MONTELUKAST TABLET (CHEWABLE)
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
02-11-2021
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
MONTELUKAST (MONTELUKAST SODIUM)
Dostopno od:
APOTEX INC
Koda artikla:
R03DC03
INN (mednarodno ime):
MONTELUKAST
Odmerek:
5MG
Farmacevtska oblika:
TABLET (CHEWABLE)
Sestava:
MONTELUKAST (MONTELUKAST SODIUM) 5MG
Pot uporabe:
ORAL
Enote v paketu:
15G/50G
Tip zastaranja:
Prescription
Terapevtsko območje:
LEUKOTRIENE MODIFIERS
Povzetek izdelek:
Active ingredient group (AIG) number: 0133823001; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2019-04-26
Lastnosti izdelka
Page 1 of 31
PRODUCT MONOGRAPH
PR
APO-MONTELUKAST
montelukast (as montelukast sodium)
4 mg and 5 mg chewable tablets
Leukotriene Receptor Antagonist
APOTEX INC.
DATE OF REVISION:
150 Signet Drive
November 2, 2021
Toronto, Ontario
M9L 1T9
SUBMISSION CONTROL NO.: 256160
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE
REACTIONS........................................................................................................
7
DRUG INTERACTIONS
.......................................................................................................10
DOSAGE AND
ADMINISTRATION......................................................................................12
OVERDOSAGE
...................................................................................................................13
ACTION AND CLINICAL
PHARMACOLOGY.......................................................................13
STORAGE AND STABILITY
................................................................................................17
DOSAGE FORMS, COMPOSITION AND
PACKAGING..........................................................17
PART II: SCIENTIFIC
INFORMATION.................................................................................18
PHARMACEUTICAL INFORMATION
..................................................................................18
CLINICAL
TRIALS..............................................................................................................19
TOX
Preberite celoten dokument
